Efficacy and safety of empagliflozin: a “real-world” experience from Saudi Arabia

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are new agents for treating type 2 diabetes. In addition to the glycemic benefits, these agents provide cardiorenal protection in patients with diabetes and without diabetes. There is consistent evidence that these agents increase the ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Muhammad Imran, Aljamei, Hadeel, Riazuddin, Muhammad, AlHaqbani, Lamia, Albalwi, Roaa, Abothenain, Fayha Farraj Mansour, Alagla, Nahlah Abdullah Mohammed, Waheed, Najeeb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: King Faisal Specialist Hospital and Research Centre 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899336/
https://www.ncbi.nlm.nih.gov/pubmed/36739502
http://dx.doi.org/10.5144/0256-4947.2023.50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899336/
https://www.ncbi.nlm.nih.gov/pubmed/36739502
http://dx.doi.org/10.5144/0256-4947.2023.50

Ejemplares similares